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PD-1: Dual guard for immunopathology 
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Despite remarkable medical development, chronic 
infectious diseases caused by the infections with persistent 
pathogens such as hepatitis B virus (HBV), hepatitis C 
virus (HCV), human immunodeficiency virus (HIV), 
and mycobacterium tuberculosis (M.tb), have not been 
conquered yet. During the chronic infection, the interaction 
between host and chronic pathogen often fosters immune 
suppressive environment. Such environment leads to the 
exhaustion of pathogen-specific T cells, resulting in the 
failure to the eradication of pathogen but the success 
to the protection of host from immunopathological 
damage. Finally, host and pathogen ensure the reduction 
of host immunopathology but the extension of pathogen 
persistence.
Under the persistence of pathogens, effector T (Teff) 
cells lose progressively their effector function such as 
cytokine production and proliferative potential and finally 
become exhausted T (Texh) cells. T-cell exhaustion can be 
caused by various factors including immune checkpoints, 
cytokines, regulatory T (Treg) cells, and altered antigen 
presenting cells (APCs) [1]. Immune inhibitory receptors, 
also known as immune checkpoints, such as programmed 
death-1 (PD-1), T-cell immunoglobulin mucin 3 (TIM-
3), cytotoxic T lymphocyte antigen-4 (CTLA-4), and 
lymphocyte activation gene-3 (LAG-3) are expressed 
on Teff cells by T-cell receptor (TCR) stimulation and 
their expressions are maintained or even increased by 
repeated TCR stimulation during chronic infection. 
Upon ligands binding, such checkpoints are triggered to 
transmit inhibitory signal into Teff cells by alone or their 
combination, which leads to the generation of Texh cells and 
the attenuation of T-cell-mediated immunopathology. The 
interaction of PD-1 and its ligand, PD-L1, has been known 
to play a critical role in the exhaustion of Teff cells. The role 
of PD-1 during chronic pathogen infection in suppressing 
T-cell function was demonstrated in the mouse model 
chronically infected with lymphocytic choriomeningitis 
virus (LCMV) [2]. This study showed that blockade of 
PD-1:PD-L1 interaction during chronic LCMV infection 
controlled viremia by restoring the function of virus-
specific Texh cells. More specifically, only PD-1
+ CD8+ T 
cells, but not PD-1- CD8+ T cells, regained their function 
upon PD-1:PD-L1 blockade, indicating that the effect of 
PD-1 on T-cell exhaustion is T-cell-intrinsic (Figure 1). 
Another interesting point was that PD-L1-deficient mice 
succumbed to chronic LCMV infection, resulting in death 
of mice within one week post-infection. PD-1:PD-L1 
pathway seemed to be also critical in protecting mice from 
persistent bacterial infection because PD-1-deficient mice 
were extraordinarily sensitive to tuberculosis [3]. These 
data strongly suggests that PD-1:PD-L1 pathway regulates 
immune-mediated tissue damage during persistent 
infection by paralyzing the pathogen-specific T cells.
The claim that PD-1 expressed by T cells is a 
culprit of T-cell exhaustion is now generally accepted 
but there can be another causing factors. One of the 
candidates is Treg cells, which play an important role for 
maintaining immunological self-tolerance and controlling 
T-cell-mediated autoreactive T-cell attack on tissue, 
because a number of studies showed the increase of 
Treg cell population during persistent viral, helminthic, 
and bacterial infections. Depletion of Treg cells in the 
mice chronically infected with LCMV was reported to 
strikingly expand functional LCMV-specific CD8+ T cells, 
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Figure 1: PD-1:PD-L1 pathway as a dual guard for 
the protection of immunopathological damage. PD-1 
is highly upregulated on Treg cells as well as Teff cells during 
chronic pathogen infection. PD-1:PD-L1 interactions between 
Teff cells and pathogen-infected cells or between Treg cells and Teff 
cells provide Teff cell exhaustion signal or Treg cell potentiation 
signal, thereby attenuating immunopathology.
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suggesting the role of Treg cells in the suppression of T-cell 
immune response during persistent pathogen infection 
[4]. However, this temporal ablation of Treg cells failed to 
not only diminish viremia but promote immunopathology 
because it also triggered upregulation of PD-L1 on 
LCMV-infected cells, which again delivers negative 
signal to PD-1-expressing T cells. It has been widely 
known that Treg cells constitutively express some immune 
checkpoints such as CTLA-4 and LAG-3. Of particular 
interest, like Texh cells, Treg cells during chronic pathogen 
infection was reported to further upregulated immune 
checkpoints including CTLA-4, LAG-3, PD-1, and TIM-
3 [4,5,6]. However, while Teff or Texh cells-expressed 
immune checkpoints debilitate their effector function, 
Treg cells-expressed ones, especially CTLA-4, have been 
reported to potentiate their suppressor function in direct or 
indirect way. For instance, CTLA-4 expressed by Treg cells 
modulates dendritic cells (DCs), thereby enhancing Treg 
cell suppressive function as positive regulator [7]. Taken 
together, albeit such a complexity, it is evident that Treg 
cells can contribute to the inhibition of T-cell response and 
the protection of tissue from T-cell-mediated pathology.
In spite of the observation that PD-1 is upregulated 
on Treg cells during chronic infection, it is less known about 
the role of PD-1 expressed by Treg cells. We recently found 
that PD-1hi Treg cells generated during chronic LCMV 
infection displayed much stronger suppressive activity 
than PD-1lo Treg cells present in steady state [6]. Either 
PD-1 blockade on PD-1hi Treg cells or PD-L1 deficiency 
on Teff cells dramatically ablated Treg cell-mediated 
suppression of Teff cell immune response, demonstrating 
the necessity of PD-1 on Treg cells and PD-L1 on Teff cells. 
These results highlight a critical role of PD-1:PD-L1 
interaction between Treg cells and PD-L1 on Teff cells and 
define PD-1 upregulated on Treg cells as a prerequisite for 
Treg cell-mediated strong suppression (Figure 1). It should 
be further investigated for the molecular mechanism by 
which whether a ligation of PD-L1 in Teff cells onto PD-
1hi Treg cells triggers PD-1 signal in Treg cells or a reverse 
signal via PD-L1 in Teff cells upon a ligation of PD-1 
provided by Treg cells inhibits Teff cell function. If the 
former is applied in vivo, PD-L1 is probably provided by 
pathogen-infected APCs as well as Teff cells. Regarding 
cell-specific expression of PD-1, our results propose that 
PD-1 expressed by Treg cells, in addition to that by Texh 
cells, contributes to the functional suppression of Teff cells 
and subsequent attenuation of immunopathology (Figure 
1).
Collectively, PD-1:PD-L1 interaction is a major 
strategy for the suppression of Teff cell-mediated immune 
response during chronic pathogen infection. Meanwhile, 
in regard to the immunopathological damage, PD-1:PD-L1 
interaction protects Teff cell-mediated tissue damage in the 
host. Of importance, PD-1:PD-L1 interaction is capable 
to occur in between Treg cells and Teff cells, in addition 
to between Teff cells and pathogen-infected cells. In both 
case, Teff cells become exhausted via direct interaction with 
separate partners and eventually fail to not only eradicate 
pathogens but also induce immunopathology in the host. 
Lastly, these studies provide perspectives regarding the 
practical and clinical treatment strategies for chronic 
infectious disease. Blockade of PD-1:PD-L1 can be useful 
to treat efficiently chronic virus infection but its potential 
risk for immunopathologic damage needs to be carefully 
monitored. 
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